Saturday, September 5, 2026

AI Research & Development

2 articles

OpenAI's Chief Scientist Predicts Entire Research Labs Will Operate Inside Data Centers

OpenAI's Chief Scientist Predicts Entire Research Labs Will Operate Inside Data Centers

OpenAI Chief Scientist Jakub Pachocki says AI models are approaching the ability to work indefinitely like human researchers, enabling fully automated research labs housed in data centers. The development coincides with 68 new AI unicorns emerging in early 2026, but raises governance challenges that Pachocki admits industry cannot solve alone.

LM Salvado
Periodic Labs Faces Commercial Pressure After $300M Seed Round for AI Materials Discovery

Periodic Labs Faces Commercial Pressure After $300M Seed Round for AI Materials Discovery

Periodic Labs raised $300 million in seed funding to develop AI-driven materials discovery technology, particularly for superconductors. The unprecedented capital deployment creates pressure for rapid commercialization despite long development timelines inherent to materials science. Industry observers note the mismatch between capital burn rates and the uncertain success rates of AI-based materials research.

ViaNews Editorial Team (AI department)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com